How to Choose a Switch Antidepressant for Working Patients With Major Depressive Disorder
How should clinicians choose and monitor a switch antidepressant for employed patients with major depressive disorder after partial SSRI response?
Patients with major depressive disorder often continue working despite substantial impairment in day-to-day and social functioning. This guide focuses on employed or self-employed partial SSRI responders in whom workplace and functional recovery are central treatment targets.
-
Identify whether the patient is a working partial responder
Apply this workflow to a patient in paid employment or self-employed who has major depressive disorder and only partial response to SSRI monotherapy. In VIVRE, 361 such patients formed a pre-specified working subgroup, making employment status clinically relevant to treatment selection.
-
Verify that residual illness burden is functionally meaningful
Assess baseline impairment with the FAST before switching treatment. In the working subgroup, mean FAST total scores were about 40 at baseline, indicating severe functional impairment despite ongoing employment.
-
Switch off the prior SSRI and initiate vortioxetine using the studied schedule
Discontinue the prior SSRI before baseline, with tapering if required, and start vortioxetine at 10 mg daily. Increase to 20 mg daily after 1 week, then adjust only between 10 and 20 mg per day through week 4 if clinically needed.
-
Track work-relevant functioning with FAST domains
Monitor FAST total score as well as the autonomy and interpersonal relationship domains, because these were the areas where vortioxetine separated from desvenlafaxine. The article defines FAST total scores of 12 to 20 as mild, 21 to 40 as moderate, and above 40 as severe functional impairment.
-
Use remission as a practical treatment target
Assess CGI-S and aim for symptomatic and functional remission, defined in the study as CGI-S score 2 or lower. In working patients at week 8, remission occurred in 36.2% of vortioxetine-treated patients versus 25.1% of desvenlafaxine-treated patients.
-
Judge success at 8 weeks by functional recovery as well as symptoms
At week 8, compare both depressive symptoms and functioning rather than relying on symptom reduction alone. In working patients, FAST total score improved more with vortioxetine than desvenlafaxine, with changes of -16.6 versus -14.1 points and a between-group difference of -2.52 points.
-
Counsel about tolerability while prioritizing adherence and satisfaction
Discuss that nausea was more common with vortioxetine, but treatment-emergent adverse event withdrawals were rare in both groups. Also note that treatment satisfaction improved more with vortioxetine in the overall study, which the authors linked to the broader clinical importance of adherence.
Clinical Considerations
- The working-patient findings come from a subgroup analysis, although this subgroup was large and pre-specified.
- The study measured overall functioning with FAST rather than direct workplace productivity outcomes.
- Results were limited to 8 weeks of treatment and may not capture longer-term occupational recovery.
- The comparator arm used desvenlafaxine 50 mg per day throughout the study.
Bottom Line
When a patient with major depressive disorder is still working but functionally impaired after an SSRI, choose the switch strategy based on functional recovery targets and monitor FAST and CGI-S closely, because vortioxetine showed better week-8 functioning and remission than desvenlafaxine in employed patients.
